HSS Journal

, 5:149

Recent Advances Toward the Clinical Application of PTH (1-34) in Fracture Healing

Authors

  • Cara A. Cipriano
    • University of Pennsylvania School of Medicine
    • Orthopaedic Trauma ServiceHospital for Special Surgery
    • Orthopaedic Trauma and Adult Reconstructive SurgeryHospital for Special Surgery
  • Lisa Shindle
    • Metabolic Bone Disease ServiceHospital for Special Surgery
  • Clément M. L. Werner
    • Orthopaedic Trauma ServiceHospital for Special Surgery
  • David L. Helfet
    • Orthopaedic Trauma ServiceHospital for Special Surgery
    • Weill-Cornell Medical Center
  • Joseph M. Lane
    • Metabolic Bone Disease ServiceHospital for Special Surgery
 

DOI: 10.1007/s11420-009-9109-8

Cite this article as:
Cipriano, C.A., Issack, P.S., Shindle, L. et al. HSS Jrnl (2009) 5: 149. doi:10.1007/s11420-009-9109-8
  • 146 Views

Abstract

PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

Copyright information

© Hospital for Special Surgery 2009